Advertisement
Screener

Protalix BioTherapeutics, Inc. (PLX) Deferred Revenue Recognized

2.8 / 5 stars · 68/120 Roast Me

Protalix BioTherapeutics, Inc. Deferred Revenue Recognized

Protalix BioTherapeutics, Inc. (PLX) reported Deferred Revenue Recognized of $4.50 million for the 3-month period ending 2019-12-31, per its 10-K filed 2020-03-12.

Discontinued › Income Statement › Other Income

us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2020-03-12

  • Protalix BioTherapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2019-12-31 was $4.50M.
  • Protalix BioTherapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2019-03-31 was -$6.91M.
  • Protalix BioTherapeutics, Inc. contract with customer, liability, revenue recognized for the quarter ending 2018-03-31 was -$2.16M.
Period endContract with Customer, Liability, Revenue Recognized 3 monthContract with Customer, Liability, Revenue Recognized 6 monthContract with Customer, Liability, Revenue Recognized 9 month
2019-12-31$4.50M
10-K · filed 2020-03-12
2019-09-30-$24.85M
10-Q · filed 2019-11-07
2019-06-30-$15.73M
10-Q · filed 2019-08-08
2019-03-31-$6.91M
10-Q · filed 2019-05-06
2018-09-30-$16.66M
10-Q · filed 2019-11-07
2018-06-30-$4.99M
10-Q · filed 2019-08-08
2018-03-31-$2.16M
10-Q · filed 2019-05-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
ANAVEX LIFE SCIENCES CORP. (AVXL)United States$0.218B-18.37
Alector, Inc. (ALEC)United States$0.213B-1.90
Compass Therapeutics, Inc. (CMPX)United States$0.204B-5.35
Aligos Therapeutics, Inc. (ALGS)United States$0.238B-0.47
Lineage Cell Therapeutics, Inc. (LCTX)United States$0.241B-10.35
Protara Therapeutics, Inc. (TARA)United States$0.198B-3.22
Alpha Cognition Inc. (ACOG)$0.185B-6.77
Coherus Oncology, Inc. (CHRS)United States$0.182B-1.63
SUTRO BIOPHARMA, INC. (STRO)United States$0.260B-3.05
PRECISION BIOSCIENCES INC (DTIL)United States$0.175B-3.95